ImmunityBio announced positive results from its QUILT 3.055 trial demonstrating long-term extended survival of 14 months to as much as five years for patients with advanced NSCLC being treated with checkpoint inhibitors.
ImmunityBio presented positive long-term OS data in NSCLC
An oral presentation of the data was presented at the World Congress on Lung Cancer. The phase 2b study of Anktiva (nogapendekin alfa inbakicept-pmln) in combination with checkpoint inhibitors Keytruda or Opdivo in multiple tumor types including NSCLC who failed CPI showed long-term overall survival of 57 percent (49/86) and 34 percent (29/86) at 12 and 18 months respectively, exceeding the current standard of care. The data continues to validate the mechanism of action of Anktiva in activating NK, CD8 killer, and Memory T cells resulting in prolonged overall survival in patients with advanced cancers. Data supports global launch of Phase 3 randomized control of ResQ trials of ANKTIVA plus KEYTRUDA or OPDIVO in 1stand 2nd line NSCLC (ResQ301 and ResQ302) versus standard of care.
Medicenna presented preclinical data from its IL-2 super-antagonist and anti-PD1-IL-2 programs
Medicenna Therapeutics, a clinical-stage immunotherapy company focused on the development of Superkines, announced that new data from two of its preclinical programs were presented orally at the Promise of Interleukin-2 Conference. MDNA209 and MDNA113 are preclinical assets based on the MDNA109 platform also used to develop MDNA11, a long-acting IL-2 Super-agonist, currently being evaluated in the Phase 1/2 ABILITY-1 clinical trial for the treatment of solid tumors. In an aggressive animal model of graft versus host disease (GvHD) MDNA209 was able to extend overall survival by 400 percent, reduce weight loss and improve clinical scores, highlighting its therapeutic potential for treating GvHD and autoimmune diseases. MDNA113 is an IL-13Rα2 tumor-targeted BiSKIT (Bifunctional SuperKine for ImmunoTherapy) which delivers an anti-PD1-IL-2 Superkine (anti-PD1-IL-2SK) directly to the tumor microenvironment (TME) where it is conditionally activated by tumor-associated proteases. MDNA113’s efficacy was significantly enhanced in mice harboring tumors engineered to overexpress IL-13Rα2, highlighting its potential to treat immunologically “cold tumors” such as pancreatic, prostate, ovarian, and breast cancers that globally affect over two million patients every year.
